With respect to previously published studies, an increased risk for congenital anomalies in general or orofacial clefts in particular, has not been suggested for albuterol. There is a lack of published data on long-acting beta2-agonists and pregnancy outcome. Thus, although neither of the two new studies reviewed above will likely change clinical practice, they both point out the need for further study of commonly-used asthma medications, and specifically, studies that incorporate direct measures of disease severity/symptom control. Reports of even small increased risks for asthma medications during pregnancy can further deter women from appropriate treatment, which in turn may result in unintended risks for both mother and baby.
Dr. Chambers is associate professor of pediatrics and family and preventive medicine at the University of California, San Diego. She is director of the California Teratogen Information Service and Clinical Research Program. Dr. Chambers is a past president of the Organization of Teratology Information Specialists and past president of the Teratology Society. She said she had no relevant financial disclosures.